NCT00006246View on ClinicalTrials.gov

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

May 31, 2003

Conditions
Brain and Central Nervous System TumorsChildhood Germ Cell TumorLeukemiaLymphomaMetastatic CancerRetinoblastomaSarcoma
Interventions
DRUG

busulfan

Trial Locations (8)

15213

Children's Hospital of Pittsburgh, Pittsburgh

27710

Duke Comprehensive Cancer Center, Durham

77030

Baylor College of Medicine, Houston

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

02115

Dana-Farber Cancer Institute, Boston

19104-4318

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Pediatric Brain Tumor Consortium

NETWORK

NCT00006246 - Busulfan in Treating Children and Adolescents With Refractory CNS Cancer | Biotech Hunter | Biotech Hunter